- Home
- PRPO vs PTHS Comparison
PRPO vs PTHS Comparison
Compare PRPO & PTHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- PTHS
- Stock Information
- Founded
- PRPO N/A
- PTHS 2002
- Country
- PRPO United States
- PTHS United States
- Employees
- PRPO N/A
- PTHS N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- PTHS
- Sector
- PRPO Industrials
- PTHS
- Exchange
- PRPO Nasdaq
- PTHS NYSE
- Market Cap
- PRPO 17.1M
- PTHS 17.1M
- IPO Year
- PRPO N/A
- PTHS N/A
- Fundamental
- Price
- PRPO $14.45
- PTHS $20.94
- Analyst Decision
- PRPO
- PTHS
- Analyst Count
- PRPO 0
- PTHS 0
- Target Price
- PRPO N/A
- PTHS N/A
- AVG Volume (30 Days)
- PRPO 17.7K
- PTHS 167.6K
- Earning Date
- PRPO 08-12-2025
- PTHS 08-12-2025
- Dividend Yield
- PRPO N/A
- PTHS N/A
- EPS Growth
- PRPO N/A
- PTHS N/A
- EPS
- PRPO N/A
- PTHS N/A
- Revenue
- PRPO $20,029,000.00
- PTHS N/A
- Revenue This Year
- PRPO N/A
- PTHS N/A
- Revenue Next Year
- PRPO N/A
- PTHS N/A
- P/E Ratio
- PRPO N/A
- PTHS N/A
- Revenue Growth
- PRPO 26.67
- PTHS N/A
- 52 Week Low
- PRPO $3.90
- PTHS $4.50
- 52 Week High
- PRPO $16.89
- PTHS $54.29
- Technical
- Relative Strength Index (RSI)
- PRPO 68.17
- PTHS N/A
- Support Level
- PRPO $14.25
- PTHS N/A
- Resistance Level
- PRPO $16.89
- PTHS N/A
- Average True Range (ATR)
- PRPO 1.08
- PTHS 0.00
- MACD
- PRPO 0.24
- PTHS 0.00
- Stochastic Oscillator
- PRPO 67.57
- PTHS 0.00
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About PTHS PELTHOS THERAPEUTICS INC
Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.